KR20240065330A - 인간 지방간염(nafld/nash)의 치료 및 역행을 위한 서방성 피르페니돈 함유 조성물의 약학적 용도 - Google Patents

인간 지방간염(nafld/nash)의 치료 및 역행을 위한 서방성 피르페니돈 함유 조성물의 약학적 용도 Download PDF

Info

Publication number
KR20240065330A
KR20240065330A KR1020247015017A KR20247015017A KR20240065330A KR 20240065330 A KR20240065330 A KR 20240065330A KR 1020247015017 A KR1020247015017 A KR 1020247015017A KR 20247015017 A KR20247015017 A KR 20247015017A KR 20240065330 A KR20240065330 A KR 20240065330A
Authority
KR
South Korea
Prior art keywords
nash
liver
nafld
pirfenidone
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020247015017A
Other languages
English (en)
Korean (ko)
Inventor
후안 소코로 아르멘다리즈 보룬다
호세 아구스틴 로헬리오 마가나 캐스트로
나디엘 헤르난데즈 알다나
Original Assignee
셀 테라피 앤드 테크놀로지, 에스.에이. 디이 씨.브이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 셀 테라피 앤드 테크놀로지, 에스.에이. 디이 씨.브이. filed Critical 셀 테라피 앤드 테크놀로지, 에스.에이. 디이 씨.브이.
Publication of KR20240065330A publication Critical patent/KR20240065330A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020247015017A 2016-11-11 2017-11-09 인간 지방간염(nafld/nash)의 치료 및 역행을 위한 서방성 피르페니돈 함유 조성물의 약학적 용도 Ceased KR20240065330A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
MX2016014775A MX364040B (es) 2016-11-11 2016-11-11 Uso farmacéutico de una composición que contiene pirfenidona de liberación prolongada (pfd-lp) para la reversión y tratamiento de la esteatohepatitis humana (nafld/nash).
MXMX/A/2016/014775 2016-11-11
KR1020197014274A KR20190084056A (ko) 2016-11-11 2017-11-09 인간 지방간염(nafld/nash)의 치료 및 역행을 위한 서방성 피르페니돈 함유 조성물의 약학적 용도
PCT/MX2017/000129 WO2018088886A1 (es) 2016-11-11 2017-11-09 Uso farmacéutico de una composición que contiene pirfenidona de liberación prolongada (pfd-lp) para la reversión y tratamiento de la esteatohepatitis humana (nafld/nash)

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020197014274A Division KR20190084056A (ko) 2016-11-11 2017-11-09 인간 지방간염(nafld/nash)의 치료 및 역행을 위한 서방성 피르페니돈 함유 조성물의 약학적 용도

Publications (1)

Publication Number Publication Date
KR20240065330A true KR20240065330A (ko) 2024-05-14

Family

ID=61193005

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020247015017A Ceased KR20240065330A (ko) 2016-11-11 2017-11-09 인간 지방간염(nafld/nash)의 치료 및 역행을 위한 서방성 피르페니돈 함유 조성물의 약학적 용도
KR1020197014274A Ceased KR20190084056A (ko) 2016-11-11 2017-11-09 인간 지방간염(nafld/nash)의 치료 및 역행을 위한 서방성 피르페니돈 함유 조성물의 약학적 용도

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020197014274A Ceased KR20190084056A (ko) 2016-11-11 2017-11-09 인간 지방간염(nafld/nash)의 치료 및 역행을 위한 서방성 피르페니돈 함유 조성물의 약학적 용도

Country Status (21)

Country Link
US (3) US20190262325A1 (cg-RX-API-DMAC7.html)
EP (1) EP3539537B1 (cg-RX-API-DMAC7.html)
JP (2) JP2019535822A (cg-RX-API-DMAC7.html)
KR (2) KR20240065330A (cg-RX-API-DMAC7.html)
CN (2) CN115969802A (cg-RX-API-DMAC7.html)
AR (1) AR110057A1 (cg-RX-API-DMAC7.html)
AU (3) AU2017358367B2 (cg-RX-API-DMAC7.html)
CA (1) CA3043300A1 (cg-RX-API-DMAC7.html)
CL (1) CL2019001280A1 (cg-RX-API-DMAC7.html)
CO (1) CO2019004799A2 (cg-RX-API-DMAC7.html)
EC (1) ECSP19031851A (cg-RX-API-DMAC7.html)
IL (1) IL266519A (cg-RX-API-DMAC7.html)
JO (1) JOP20190102A1 (cg-RX-API-DMAC7.html)
MA (1) MA45754A1 (cg-RX-API-DMAC7.html)
MX (1) MX364040B (cg-RX-API-DMAC7.html)
PE (1) PE20191149A1 (cg-RX-API-DMAC7.html)
PH (1) PH12019501047A1 (cg-RX-API-DMAC7.html)
RU (1) RU2019116422A (cg-RX-API-DMAC7.html)
UY (1) UY37478A (cg-RX-API-DMAC7.html)
WO (1) WO2018088886A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201903012B (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007009796A (es) 2007-08-14 2009-02-25 Cell Therapy And Technology S Gel conteniendo pirfenidona.
MX2011007675A (es) 2011-07-19 2012-07-11 Cell Therapy And Technology S A De C V Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas.
MX346763B (es) 2012-03-28 2017-03-31 Cell Therapy And Tech S A De C V Composición tópica semisólida conteniendo pirfenidona y dialil óxido de disulfuro modificado (odd-m) para eliminar o prevenir el acné.
MX356551B (es) 2012-08-23 2018-06-04 Grupo Medifarma S A De C V Star Composición antiséptica, antiseborreica y exfoliante para eliminar o prevenir el acné.
MX366086B (es) 2017-08-15 2019-06-27 Cell Therapy And Tech S A De C V Composicion topica semisolida conteniendo un agente antimicrobiano y pirfenidona para el tratamiento de daños cronicos de la piel.
JP2021504479A (ja) * 2017-11-28 2021-02-15 アイガー・バイオファーマシューティカルズ・インコーポレイテッドＥｉｇｅｒ Ｂｉｏｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 非アルコール性脂肪性肝炎の処置のための方法および医薬組成物
MX368750B (es) 2018-08-31 2019-10-15 Cell Therapy And Tech S A De C V Composiciones farmaceuticas semisolidas de base oleosa conteniendo pirfenidona para su aplicacion en la reparacion tisular.
WO2020115774A1 (en) 2018-12-06 2020-06-11 Cipla Limited High drug load extended release formulations
AU2021365528A1 (en) * 2020-10-23 2023-06-15 Hq Han Bifunctional antagonists of tumor necrosis factor-alpha and transforming growth factor-beta and uses thereof
CN116159056A (zh) * 2023-03-09 2023-05-26 中南大学湘雅医院 一种氟非尼酮在制备非酒精性脂肪性肝炎药物中的应用
CN117007806A (zh) * 2023-09-21 2023-11-07 中国人民解放军军事科学院军事医学研究院 靶向肝巨噬细胞内lxr用于控制慢乙肝进展

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60234812D1 (de) * 2001-01-29 2010-02-04 Shionogi & Co Arzneipräparat, das als wirkstoff 5-methyl-1-phenyl-2-(1h)-pyridon enthält
WO2005000227A2 (en) * 2003-06-06 2005-01-06 Intermune, Inc. Methods of treating tnf-mediated disorders
CN100542532C (zh) * 2004-05-24 2009-09-23 上海睿星基因技术有限公司 吡非尼酮在制备治疗肝损伤坏死和急性肺损伤的药物中的用途
US20110288134A1 (en) * 2008-10-29 2011-11-24 Pacific Therapeutics Ltd. Composition and method for treating fibrosis
US7635707B1 (en) * 2008-11-10 2009-12-22 Intermune, Inc. Pirfenidone treatment for patients with atypical liver function
CN101972236A (zh) * 2010-10-13 2011-02-16 北京诚创康韵医药科技有限公司 一种含吡非尼酮的缓释制剂
MX2011007675A (es) * 2011-07-19 2012-07-11 Cell Therapy And Technology S A De C V Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas.
CN102488660A (zh) * 2011-12-15 2012-06-13 西安天一秦昆制药有限责任公司 一种含吡非尼酮的缓释微丸
CN103550242B (zh) * 2013-11-22 2015-07-15 四川国康药业有限公司 一种治疗肝纤维化的药物组合物及其制备方法

Also Published As

Publication number Publication date
US20190262325A1 (en) 2019-08-29
KR20190084056A (ko) 2019-07-15
MX364040B (es) 2019-04-11
IL266519A (en) 2019-07-31
JP2019535822A (ja) 2019-12-12
US20250325530A1 (en) 2025-10-23
PE20191149A1 (es) 2019-09-02
AU2024200737A1 (en) 2024-02-22
JP2022173344A (ja) 2022-11-18
CN115969802A (zh) 2023-04-18
EP3539537B1 (en) 2026-07-15
EP3539537A1 (en) 2019-09-18
CO2019004799A2 (es) 2019-07-31
CA3043300A1 (en) 2018-05-17
RU2019116422A3 (cg-RX-API-DMAC7.html) 2021-04-09
RU2019116422A (ru) 2020-12-11
AR110057A1 (es) 2019-02-20
MA45754A1 (fr) 2019-12-31
AU2017358367B2 (en) 2023-11-09
CN110248646A (zh) 2019-09-17
MX2016014775A (es) 2018-05-10
US20230181550A1 (en) 2023-06-15
CL2019001280A1 (es) 2019-07-19
ECSP19031851A (es) 2019-06-30
WO2018088886A1 (es) 2018-05-17
AU2017358367A1 (en) 2019-05-30
PH12019501047A1 (en) 2019-12-11
ZA201903012B (en) 2020-09-30
UY37478A (es) 2018-05-31
AU2026200298A1 (en) 2026-02-05
JOP20190102A1 (ar) 2019-05-06

Similar Documents

Publication Publication Date Title
US20250325530A1 (en) Pharmaceutical use of an extended-release composition containing pirfenidone for the treatment and reversal of human steatohepatitis (nafld/nash)
US11291694B2 (en) Composition for treating or preventing metabolic disease, containing, as active ingredient, extracellular vesicles derived from Akkermansia muciniphila bacteria
Wu et al. Orexigenic hormone ghrelin ameliorates gut barrier dysfunction in sepsis in rats
JP6542275B2 (ja) ＧＰＣＲ１９作用剤を有効成分として含有するアレルギー性皮膚疾患の予防又は治療用の組成物｛Ｃｏｍｐｏｓｉｔｉｏｎ ｆｏｒ ｐｒｅｖｅｎｔｉｎｇ ｏｒ ｔｒｅａｔｉｎｇ ａｌｌｅｒｇｉｃ ｄｅｒｍａｔｉｔｉｓ ｃｏｍｐｒｉｓｉｎｇ ＧＰＣＲ１９ ａｇｏｎｉｓｔ ａｓ ａｎ ａｃｔｉｖｅ ｉｎｇｒｅｄｉｅｎｔ｝
US20170049773A1 (en) Pharmaceutical composition containing gpr119 ligand as active ingredient for preventing or treating non-alcoholic fatty liver disease
Lin et al. Differential action of TGR5 agonists on GLP-2 secretion and promotion of intestinal adaptation in a piglet short bowel model
CN109550051B (zh) 组蛋白去甲基化酶kdm6a抑制剂在制备肥胖症治疗药物的用途
RU2727142C2 (ru) Бисамидное производное дикарбоновой кислоты в качестве средства, стимулирующего регенерацию тканей и восстановление сниженных функций тканей
JP2023106431A (ja) 非アルコール性脂肪性肝疾患と非アルコール性脂肪性肝炎の予防および／または処置に使用するための化合物
JP2021527669A (ja) 線維症の軽減又は治療のための組成物及び方法
HK40092172A (en) Pharmaceutical use of an extended-release composition containing pirfenidone for the treatment and reversal of human steatohepatitis
JP2025507962A (ja) 炎症性腸疾患の治療のためのｇｐｒ１２０アゴニスト
KR101706868B1 (ko) 2-아미노-2-노보네인카복실산을 함유하는 지방간염의 예방 또는 치료용 조성물
RU2807743C1 (ru) Применение 5-пентадецилрезорцинола для повышения доли Akkermansia muciniphila в микробиоме человека
CN112641779B (zh) Gw441756在制备预防和/或治疗脂肪肝药物中的应用
JP2021526552A (ja) 血糖制御を改善し、炎症性腸疾患を処置するための構造修飾脂肪酸
US12285434B2 (en) Therapeutic, preventive, or improvement agent for inflammatory disease and allergic disease
Abd-Elsattar et al. A Histological Study of The Protective Role of Intermittent Fasting and Probiotics on Indomethacin Induced Colitis in Adult Male Albino Rats
CN119970721A (zh) 吲哚乙酸在制备预防和/或治疗脂肪肝肝纤维化药物中的应用
CN118948838A (zh) 延命草素及其组合物在制备预防和/或治疗非酒精性脂肪肝药物中的应用
CN118078849A (zh) 白头翁皂苷b4衍生物a3-9在制备防治炎症性肠病药物中的应用
McDaniel et al. Sa1453-Secretin Knockout Reduces Liver Damage in Alcoholic Liver Disease
Kobayashi et al. Influence of the Digested Products of Royal Jelly on Insulin Levels in KK-Ay Mice
JP2011219439A (ja) レチノイン酸受容体リガンドによるインスリン抵抗性改善作用
Ichikawa et al. S1745 Anti-Inflammatory Effects of Opc-6535; PDE4 May Be a New Therapeutic Target in Inflammatory Bowel Disease

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20240503

Application number text: 1020197014274

Filing date: 20190517

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20240603

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20241022

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20250103

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D